U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Pharvaris gains after genetic disorder drug meets late-stage trial goal
Pharvaris' genetic disorder drug meets main goal in late-stage trial
Pharvaris N.V. reports results for the quarter ended June 30 - Earnings Summary
Switzerland's Pharvaris Q2 loss narrows, cash rises to €318 mln
Switzerland's Pharvaris Q1 loss per share narrows
Brief: Pharvaris Announces Pricing Of $115 Million Underwritten Offering Of Ordinary Shares
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
U.S. STOCKS ON THE MOVE-Wendy's, Bristol Myers Squibb, Macy's
Pharvaris jumps as oral therapy for genetic disorder meets main goal in late-stage trial
Brief: Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study
Biopharma firm Pharvaris' Q3 cash at €329 mln, progressing with Phase 3 trials
Pharvaris NV reports results for the quarter ended June 30 - Earnings Summary
Pharvaris NV expected to post a loss of 77 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tesla, Northern Trust, General Dynamics
Drug developer Pharvaris falls after upsized $175 million raise